Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.

Current Alzheimer research - 22 Feb 2018

de Oliveira Fabricio Ferreira, Chen Elizabeth Suchi, Smith Marilia Cardoso, Bertolucci Paulo Henrique Ferreira

Abstract excerpt

BACKGROUND: While the angiotensin-converting enzyme degrades amyloid-β, angiotensinconverting enzyme inhibitors (ACEis) may slow cognitive decline by way of cholinergic effects, by increasing brain substance P and boosting the activity of neprilysin, and by modulating glucose homeostasis and augmenting the secretion of adipokines to enhance insulin sensitivity in patients with Alzheimer's disease dementia (AD)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angiotensin-Converting Enzyme Inhibitors

Share to Apolipoprotein E4

Share to Follow-Up Studies

Share to Outcome Assessment, Health Care

Share to Peptidyl-Dipeptidase A

Share to Pharmacogenetics

Source

Identifiers

PMID: 29034839
DOI: 10.2174/1567205014666171016101816

Genes

ACE
APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.PMID 29034839Read ↗

Pharmacogenetics of angiotensin modulators according to APOE-ϵ4 alleles and the ACE insertion/deletion polymorphism in Alzheimer's disease.Semantic proximity Read ↗

Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease.Semantic proximity Read ↗

Behavioural effects of the ACE insertion/deletion polymorphism in Alzheimer's disease depend upon stratification according to APOE-ϵ4 carrier status.Semantic proximity Read ↗

Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia.Semantic proximity Read ↗

Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease.Semantic proximity Read ↗

Pharmacogenomics in Alzheimer's disease.Semantic proximity Read ↗

Pharmacogenetic Considerations in the Treatment of Alzheimer’s DiseaseSemantic proximity Read ↗

Influence of pharmacogenetic factors on Alzheimer's disease therapeutics.Semantic proximity Read ↗

The Impact of Angiotensin-Converting Enzyme Gene on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease.Semantic proximity Read ↗

ACE inhibition increases Alzheimer’s disease risk by promoting tau phosphorylationSemantic proximity Read ↗

Pharmacogenomics for the treatment of dementia.Semantic proximity Read ↗

Opportunities in pharmacogenomics for the treatment of Alzheimer’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.